



George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine, Emeritus

Medicine - Oncology

 Curriculum Vitae available Online

CLINICAL OFFICE (PRIMARY)

- **Medical Oncology**

875 Blake Wilbur Dr

Clinic A MC 6562

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 736-4167

Bio

BIO

I conduct clinical research on a variety of gastrointestinal cancers and provide care for patients with those cancers. We have trials of combined modality therapy (surgery +/- radiation +/- chemotherapy) on gastric, esophageal, pancreas and rectal cancers. We also perform phase I and II trials of biologically targeted agents as well as newer immunotherapeutics. In collaboration with a number of colleagues, we conduct translational studies analyzing novel imaging (e.g. contrast enhanced ultrasound and perfusion scans) and molecular biomarkers (e.g. CDX2 as a prognostic and predictive factor in colon cancer and matrix metalloproteinases as prognostic factors in pancreas cancer). Neuroendocrine tumors, pancreas, colorectal and gastro-esophageal cancers have been areas of particular research focus with multiple therapeutic and translational studies devote to each. Examples of recently completed trials include a randomized phase III trial of a vaccine (algenpantucel) for resected pancreas cancer, phase Ib trial of anti-PD-L1 and separate phase II trials using PD-1 antibody for tumors with micro satellite instability and chemotherapy with angiogenesis inhibitors for advanced neuroendocrine tumors and gastro-esophageal adenocarcinomas. Currently active areas of study include combining immunomodulating antibodies in combination therapy and randomized phase II colon cancer trials of an antibody to interleukin 1 or a first in class agent known as RadioRx. Participation and leadership in NCI cooperative group protocols gives our patients access to the randomized trials that hope to establish new standards of care for a variety of GI cancers.

CLINICAL FOCUS

- Cancer > GI Oncology
- Medical Oncology
- Oncology
- Cancer of the Pancreas
- Colorectal Neoplasms
- Neuroendocrine Tumors
- gastro esophageal cancer
- gastric cancer

- stomach cancer
- pancreatic neoplasms
- small intestinal cancer
- cholangiocarcinoma
- bile duct cancer
- gall bladder cancer
- carcinoid tumor
- appendiceal cancer
- anal cancer

ACADEMIC APPOINTMENTS

- Emeritus (Active) Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Director, Cancer Clinical Trials Office, (2004-2013)
- Vice Chair GI Committee, ECOG-ACRIN, (2015- present)
- Physician Leader, GI Clinical Research Group, (2010-2015)
- Physician Leader, GI Oncology Disease Management Group, (2011-2015)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Chair, 2020 GI Symposium Steering Committee (2019 - present)
- Co-Chair Scientific Advisory Board, Neuroendocrine Tumor Research Foundation (2011 - present)
- member, NCI GI Steering Committee, National Cancer Institute (2017 - present)
- Member, Scientific and Medical Advisory Board, Pancreatic Cancer Action Network (2012 - present)
- Vice Chair, GI Committee, ECOG/ACRIN (2015 - present)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2024)
- Medical Education: Stanford University School of Medicine (1987) CA
- Fellowship: Stanford University Hematology and Oncology Fellowship (1993) CA
- Residency: Stanford University Internal Medicine Residency (1989) CA
- Internship: Stanford University Internal Medicine Residency (1988) CA
- BS, Stanford University , Biology (1976)
- PhD, Stanford University , Cancer Biology (1987)
- MD, Stanford University , Medicine (1987)
- Residency, Stanford University , Internal Medicine (1989)
- Fellowship, Stanford University , Medical Oncology (1993)

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Clinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials.

CLINICAL TRIALS

- A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors, Recruiting
- Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer, Recruiting
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors, Not Recruiting
- A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer, Not Recruiting
- A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer, Not Recruiting
- A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer, Not Recruiting
- A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma, Not Recruiting
- A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma, Not Recruiting
- A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer, Not Recruiting
- A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy, Not Recruiting
- A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours, Not Recruiting
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC), Not Recruiting
- A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors, Not Recruiting
- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors, Not Recruiting
- A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma, Not Recruiting
- A Study of Nilotinib Versus Imatinib in GIST Patients, Not Recruiting
- A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors, Not Recruiting
- A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors, Not Recruiting
- A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors, Not Recruiting
- A Study of XmAb®18087 in Subjects With NET and GIST, Not Recruiting
- A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST), Not Recruiting
- A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors, Not Recruiting
- A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma, Not Recruiting
- An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome, Not Recruiting
- Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors, Not Recruiting
- Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair, Not Recruiting
- Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer, Not Recruiting

- Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread, Not Recruiting
- EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx, Not Recruiting
- Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours, Not Recruiting
- Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma, Not Recruiting
- Epcadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer, Not Recruiting
- Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma, Not Recruiting
- Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer, Not Recruiting
- GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab, Not Recruiting
- Immunotherapy Study for Surgically Resected Pancreatic Cancer, Not Recruiting
- Ipilimumab and Local Radiation for Selected Solid Tumors, Not Recruiting
- Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy, Not Recruiting
- Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy, Not Recruiting
- Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-III Anal Cancer, Not Recruiting
- Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer, Not Recruiting
- Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery, Not Recruiting
- Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors, Not Recruiting
- Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy, Not Recruiting
- Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination, Not Recruiting
- Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer, Not Recruiting
- Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer, Not Recruiting
- Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer, Not Recruiting
- Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast, Not Recruiting
- Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer, Not Recruiting
- Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors, Not Recruiting
- Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC, Not Recruiting
- PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery, Not Recruiting
- Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma, Not Recruiting
- Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors, Not Recruiting
- Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery, Not Recruiting
- Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer, Not Recruiting
- Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer, Not Recruiting
- Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC), Not Recruiting
- Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C), Not Recruiting
- Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164), Not Recruiting

- Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177), Not Recruiting
- Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer, Not Recruiting
- TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome), Not Recruiting
- Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms, Not Recruiting
- Telotristat Etiprate for Carcinoid Syndrome Therapy, Not Recruiting
- Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors, Not Recruiting
- Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer, Not Recruiting
- A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies, Not Specified
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer., Not Specified
- Clinical and Pathologic Studies in Neuroendocrine Tumors, Not Specified
- Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers, Not Specified
- Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma, Not Specified
- Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study, Not Specified
- Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors, Not Specified

Publications

PUBLICATIONS

- **Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors.** *Nature biotechnology*
Lu, G., Hickey, J. W., Haist, M., Qin, X., Zhao, E., Naveed, A., Forgo, E., Baertsch, M. A., Mani, L., Rovira-Clavé, X., Finegersh, A., Goltsev, Y., Caraccio, et al
2026
- **KRAS Variant Frequency and Colorectal Cancer-Specific Survival by Race and Ethnicity.** *JAMA network open*
Rodriguez, G. M., Aljehani, M., DePuy, D., Patel, S. R., Fisher, G. A., Lin, A. Y.
2026; 9 (3): e261585
- **Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma.** *Journal for immunotherapy of cancer*
O'Reilly, E. M., Cabanski, C. R., Lyman, J. P., Wainberg, Z. A., Fisher, G. A., Wolff, R. A., Ko, A. H., O'Hara, M. H., Spencer, C. N., Yu, J. X., Da Silva, D. M., Padrón, L. J., Arnott, et al
2026; 14 (1)
- **A deep learning-based automated pipeline for colorectal cancer detection in contrast-enhanced CT images.** *Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society*
Qiu, C., Miller, S., Subramanian, B., Ryu, A., Zhang, H., Fisher, G. A., Shah, N. H., Mongan, J., Langlotz, C., Poulos, P., Shen, J.
2026; 128: 102717
- **Sex disparity in survival outcomes of advanced gastric adenocarcinoma.** *BJC reports*
Pan, M., Tong, M. M., Stover, J., Huang, T., Dang, A., Jiang, C., Achacoso, N. S., Bien, J., Solorzano, A. V., Tse, P., Chung, E., Kanakaveti, V. P., Felsher, et al
2025; 3 (1): 58
- **Clinico-radiographic predictors of overall survival in stage II-III pancreatic cancer.**
Xu, Q., Toesca, D., Vitzthum, L., Jamalain, A., Schueler, E., Alkim, E., Baclay, J., Chang, D., Gevaert, O., Fisher, G. A., Itakura, H.
LIPPINCOTT WILLIAMS & WILKINS.2025: e16457
- **Association of HER2 amplification or overexpression with overall survival in advanced upper gastrointestinal adenocarcinomas.** *BJC reports*

- Pan, M., Dang, A., Huang, T., Stover, J., Tong, M. M., Jiang, C., Achacoso, N. S., Bien, J., Solorzano, A. V., Tse, P., Chung, E., Kanakaveti, V. P., Felsher, et al
2025; 3 (1): 31
- **Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX): Two-Year primary outcome analysis.** *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*
Klebaner, D., Brown, E., Fisher, G. A., Shelton, A., Johnson, T. P., Shaheen, S., Chen, C., Heestand, G., Holden, T., Bien, J., King, D. A., Dawes, A. J., Morris, et al
2025; 207: 110884
 - **A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.** *Targeted oncology*
Eng, C., Lakhani, N. J., Philip, P. A., Schneider, C., Johnson, B., Kardosh, A., Chao, M. P., Patnaik, A., Shihadeh, F., Lee, Y., Song, K., Jin, D., Huo, et al
2025
 - **Prognostic and biological divergence of upper gastrointestinal adenocarcinomas.**
Dang, A., Pan, M., Stover, J., Huang, T., Tong, M., Jiang, C., Habel, L. A., Achacoso, N., Bien, J., Solorzano-Pinto, A., Tse, P., Chung, E., Felsher, et al
LIPPINCOTT WILLIAMS & WILKINS.2025: 350
 - **Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.** *Nature medicine*
Lopez, J., Powles, T., Braiteh, F., Siu, L. L., LoRusso, P., Friedman, C. F., Balmanoukian, A. S., Gordon, M., Yachnin, J., Rottey, S., Karydis, I., Fisher, G. A., Schmidt, et al
2025
 - **Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which is Best?** *Annals of surgery*
Ahmad, M. U., Javadi, C. S., Chang, J. D., Forgó, E., Delitto, D. J., Dua, M. M., Fisher, G. A., Heestand, G. M., Chang, D. T., Pollom, E., Vitzthum, L. K., Kirane, A., Lee, et al
2024
 - **Utility of radiomic features in predicting clinical outcomes in stage II-III pancreatic cancer.**
Itakura, H., Xu, Q., Toesca, D., Vitzthum, L., Jamalian, A., Schueler, E., Alkim, E., Baclay, J., Chang, D., Fisher, G. A.
LIPPINCOTT WILLIAMS & WILKINS.2024: 74
 - **Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma.** *Nature communications*
Till, J. E., McDaniel, L., Chang, C., Long, Q., Pfeiffer, S. M., Lyman, J. P., Padrón, L. J., Maurer, D. M., Yu, J. X., Spencer, C. N., Gherardini, P. F., Da Silva, D. M., LaVallee, et al
2024; 15 (1): 5763
 - **Advancing Clinical Trial Equity through Integration of Telehealth and Decentralized Treatment.** *JNCI cancer spectrum*
Brown, E., Albert Fisher, G., Shelton, A., Chang, D. T., Pollom, E.
2024
 - **Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX).**
Pollom, E. L., Fisher, G. A., Shelton, A., Johnson, T., Chen, C., Jackson, S., Shaheen, S., Holden, T., Bien, J., King, D., Morris, A. M., Kin, C., Dawes, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
 - **Clinical and translational results from REVOLUTION cohorts A (nivolumab plus ipilimumab plus chemotherapy) and B (hydroxychloroquine plus ipilimumab plus chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma.**
O'Reilly, E. M., Wainberg, Z. A., Fisher, G. A., Wolff, R. A., Ko, A. H., O'Hara, M. H., Spencer, C. N., Yu, J., Da Silva, D. M., Padron, L. J., Lyman, J. P., Moore, J. S., Peng, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
 - **Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.** *Journal for immunotherapy of cancer*
Shen, J., Choi, Y. L., Lee, T., Kim, H., Chae, Y. K., Dulken, B. W., Bogdan, S., Huang, M., Fisher, G. A., Park, S., Lee, S. H., Hwang, J. E., Chung, et al
2024; 12 (2)

- **Predicting rapid progression and overall survival in stage II-III pancreatic cancer using a CT-based radiomic signature.**
Xu, Q., Toesca, D., Schueler, E., Jamalian, A., Alkim, E., Chang, D., Fisher, G. A., Vitzthum, L., Gevaert, O., Itakura, H.
LIPPINCOTT WILLIAMS & WILKINS.2024: 706
- **Clinicopathological features and clinical outcomes in individuals with Krukenberg tumors of colorectal origin.**
Bergstrom, C. P., Wang, C., King, D., Lin, A. Y., Fisher, G. A.
LIPPINCOTT WILLIAMS & WILKINS.2024: 191
- **Early results of a pancreas cancer learning health network: Canopy Cancer Collective.**
Herman, J. M., Alyesh, A., Korah, B., Narang, A., Deperalta, D., Lowy, A. M., Ejaz, A., Tempero, M. A., Fisher, G. A., Coveler, A. L., Aguilera, T., Goodman, K. A., Donahue, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: 645
- **KRAS Sequence Variation as Prognostic Marker in Patients With Young- vs Late-Onset Colorectal Cancer. *JAMA network open***
Aljehani, M. A., Bien, J., Lee, J. S., Fisher, G. A., Lin, A. Y.
2023; 6 (11): e2345801
- **ASO Visual Abstract: Patterns of Recurrence after Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation. *Annals of surgical oncology***
Hui, C., Ewongwo, A., Lau, B., Fisher, G., Delitto, D., Poultides, G., Ho, Q. A., Rahimy, E., Pollom, E., Chang, D. T., Vitzthum, L. K.
2023
- **Patterns of Recurrence After Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation. *Annals of surgical oncology***
Hui, C., Ewongwo, A., Lau, B., Fisher, G., Delitto, D., Poultides, G., Ho, Q., Rahimy, E., Pollom, E., Chang, D. T., Vitzthum, L. K.
2023
- **Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With ¹⁷⁷Lutetium DOTATATE: A Case Report. *Cureus***
Zhang, V., Taparra, K., Fisher, G., Aparici, C., Soltys, S. G.
2023; 15 (9): e45327
- **A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors. *American journal of clinical oncology***
Fracasso, P. M., Fisher, G. A., Goodner, S. A., Beumer, J. H., Egorin, M. J., Fears, C. L., Wildi, J. D., Jones, G. J., Pearce, T. E., Sikic, B. I.
2023
- **Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial. *The oncologist***
Stockton, S., Catalano, P., Cohen, S. J., Burtness, B. A., Mitchell, E. P., Dotan, E., Lubner, S. J., Kumar, P., Mulcahy, M. F., Fisher, G. A., Crandall, T. L., Benson, A.
2023
- **Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates. *JCO precision oncology***
King, D. A., Smith, A. R., Pineda, G., Nakano, M., Michelini, F., Goedegebuure, S. P., Thyparambil, S., Liao, W. L., McCormick, A., Ju, J., Cioffi, M., Zhang, X., Hundal, et al
2023; 7: e2100489
- **Validation of a Resectability Scoring System for Prediction of Pancreatic Adenocarcinoma Surgical Outcomes. *Annals of surgical oncology***
Toesca, D. A., Susko, M., von Eyben, R., Baclay, J. R., Pollom, E. L., Jeffrey, R. B., Poullos, P. D., Poultides, G. A., Fisher, G. A., Visser, B. C., Koong, A. C., Feng, M., Chang, et al
2023
- **Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemioimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC).**
Lyman, J. P., Cabanski, C. R., Maddock, S., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Rahma, O. E., Fisher, G. A., Gabriel, P., Doucette, A., Zheng-Lin, B., Maloy, M. A., Dugan, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: 757
- **Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in Gastric Adenocarcinoma. *JCO precision oncology***

- King, D. A., Weiel, J. J., Reyes, R., Mills, M., Itchon, A., Fisher, G. A., Ford, J. M., Suarez, C. J.
2023; 7: e2200093
- **Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001+irinotecan vs. regorafenib plus irinotecan in third/fourth-line colorectal cancer.**
Reid, T. R., Abrouk, N., Oronsky, B., Caroen, S., Fisher, G. A.
LIPPINCOTT WILLIAMS & WILKINS.2023: 97
 - **ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer.** *Clinical colorectal cancer*
Reid, T. R., Abrouk, N., Caroen, S., Oronsky, B., Stirn, M., Larson, C., Beale, K., Knox, S. J., Fisher, G.
2022
 - **Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation.** *JACC. CardioOncology*
Nguyen, A. T., Berry, G. J., Witteles, R. M., Le, D. T., Wu, S. M., Fisher, G. A., Zhu, H.
2022; 4 (5): 727-730
 - **EXPLORATORY PLATFORM TRIAL TO EVALUATE IMMUNOTHERAPY COMBINATIONS WITH CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC ADENOCARCINOMA (REVOLUTION)**
Lyman, J., O'Reilly, E., Wainberg, Z., Fisher, G., Wolff, R., Ko, A., O'Hara, M., Singh, H., Amaravadi, R., Kimmelman, A., Collison, E., Khalil, D., Schmidberger, et al
BMJ PUBLISHING GROUP.2022: A687
 - **A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.** *Investigational new drugs*
Rajdev, L., Lee, J., Libutti, S. K., Benson, A. B., Fisher, G. A., Kunz, P. L., Hendifar, A. E., Catalano, P., O'Dwyer, P. J.
2022
 - **A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Kunz, P. L., Graham, N. T., Catalano, P. J., Nimeiri, H. S., Fisher, G. A., Longacre, T. A., Suarez, C. J., Martin, B. A., Yao, J. C., Kulke, M. H., Hendifar, A. E., Shanks, J. C., Shah, et al
2022: 101200JCO2201013
 - **Building a learning network to accelerate improvement in pancreas cancer care and outcomes: Canopy Cancer Collective**
Herman, J. M., Stricker, C., Myers, S., Korah, B., Narang, A., Hacker-Prietz, A., Deperalta, D., Hong, T. S., Dullard, A., Lowy, A., Ejaz, A., Tempero, M. A., Fisher, et al
LIPPINCOTT WILLIAMS & WILKINS.2022: 368
 - **Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.** *Nature medicine*
Padron, L. J., Maurer, D. M., O'Hara, M. H., O'Reilly, E. M., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., Cabanski, C. R., Yu, J. X., Pfeiffer, et al
2022
 - **Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.**
Eads, J., Catalano, P. J., Fisher, G. A., Rubin, D., Jagaru, A., Klimstra, D. S., Konda, B., Kwong, M. S., Chan, J. A., De Jesus-Acosta, A., Halfdanarson, T., Shaib, W., Soares, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
 - **EA2183: A phase III study of consolidative radiotherapy in patients with oligometastatic HER2-negative esophageal and gastric adenocarcinoma**
Uboha, N., Graham, N., Rajdev, L., Gibson, M. K., Fisher, G. A., Lin, S. H., Chakravarthy, B., O'Dwyer, P. J.
LIPPINCOTT WILLIAMS & WILKINS.2022
 - **A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).**
Kunz, P. L., Graham, N., Catalano, P. J., Nimeiri, H., Fisher, G. A., Longacre, T. A., Suarez, C. J., Rubin, D., Yao, J. C., Kulke, M. H., Hendifar, A., Shanks, J., Shah, et al
LIPPINCOTT WILLIAMS & WILKINS.2022

- **Circulating KRAS variant-specific shedding and association with survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving chemoimmunotherapy**
Till, J., McDaniel, L., Pfeiffer, S. M., Maurer, D. M., Yu, J., Spencer, C., Lyman, J. P., Cabanski, C. R., Da Silva, D. M., Abbott, C., Boyle, S., Rahma, O. E., Fisher, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **The inflamed immune phenotype (IIP): A clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across > 16 primary tumor types**
Shen, J., Choi, Y., Lee, T., Kim, H., Chae, Y., Dulken, B., Bogdan, S., Huang, M., Fisher, G. A., Park, S., Lee, S., Hwang, J., Chung, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer.**
Padron, L. J., Maurer, D. M., O'Hara, M. H., O'Reilly, E., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G. A., Rahma, O. E., Lyman, J. P., Cabanski, C. R., Yu, J., Pfeiffer, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Radiographic, Biochemical, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best?**
Javadi, C., Chang, J., Forgo, E., Ahmad, M., Fisher, G. A., Chang, D. T., Delitto, D. J., Dua, M. M., Lee, B., Visser, B. C., Norton, J. A., Poultides, G. A.
SPRINGER.2022: 351
- **Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up.** *The oncologist*
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Iagaru, A., Mari Aparici, C.
2022
- **Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience**
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Moradi, F., Nguyen, J., Franc, B. L., Iagaru, A., Aparici, C.
LIPPINCOTT WILLIAMS & WILKINS.2022: E42-E43
- **Safety, Pharmacodynamic, and Antitumor Activity of Tidutamab, an SSTR2 x CD3 Bispecific Antibody, in Subjects With Advanced Neuroendocrine Tumors**
El-Rayes, B. F., Hendifar, A. E., Pant, S., Wilky, B. A., Reilley, M. J., Benson, A. B., Chow, W. A., Konda, B., Starr, J., Ahn, D. H., Kunz, P. L., Strosberg, J. R., Eads, et al
LIPPINCOTT WILLIAMS & WILKINS.2022: E58
- **MULTIOMIC BIOMARKER SIGNATURES IDENTIFY SUBSETS OF PATIENTS WHO MAY BENEFIT FROM EITHER NIVOLUMAB OR SOTIGALIMAB IN COMBINATION WITH CHEMOTHERAPY IN METASTATIC PANCREATIC CANCER**
Maurer, D., Yu, J., Sklodowski, K., Tognetti, M., Reiter, L., Bruderer, R., Vowinkel, J., Pfeiffer, S., O'Hara, M., O'Reilly, E., Wolff, R., Wainberg, Z., Ko, et al
BMJ PUBLISHING GROUP.2021: A370
- **Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair deficient pancreatic cancer.** *Immunotherapy*
Tsang, E. S., Walker, E. J., Carnevale, J., Fisher, G. A., Ko, A. H.
2021
- **Baseline level and early on-treatment clearance of circulating mutant KRAS in metastatic pancreatic ductal adenocarcinoma treated with chemotherapy with or without immunotherapy.**
Till, J. E., Abdalla, A., Bhagwat, N., Black, T. A., Wang, Z., Yee, S. S., Gherardini, P., Kitch, L. J., Selinsky, C., Lyman, J., LaVallee, T., Fisher, G. A., Rahma, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in-A trial of the ECOG-ACRIN Cancer Research Group (EA2174).**
Eads, J., Weitz, M., Catalano, P. J., Gibson, M. K., Rajdev, L., Khullar, O., Lin, S. H., Gatsonis, C., Wistuba, I., Sanjeevaiah, A., Benson, A., Bahary, N., Spencer, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers.** *Cancer chemotherapy and pharmacology*

- Ma, W. W., Zhu, M., Lam, E. T., Diamond, J. R., Dy, G. K., Fisher, G. A., Goff, L. W., Alberts, S., Bui, L. A., Sanghal, A., Kotheekar, M., Khopade, A., Chimote, et al
2021
- **CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.** *The Lancet. Oncology*
O'Hara, M. H., O'Reilly, E. M., Varadhachary, G. n., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G. n., Rahma, O. n., Lyman, J. P., Cabanski, C. R., Mick, R. n., Gherardini, P. F., Kitch, et al
2021; 22 (1): 118–31
 - **Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.** *Journal of Clinical Oncology*
Shen, J., Lee, T., Hwang, J., Choi, Y., Lee, S., Kim, H., Chung, J., Bogdan, S., Huang, M., Raclin, T., Fisher, G. A., Pereira, S., Park, et al
2021; 39
 - **CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study** *LANCET ONCOLOGY*
O'Hara, M. H., O'Reilly, E. M., Varadhachary, G., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., Cabanski, C. R., Mick, R., Gherardini, P., Kitch, et al
2021; 22 (1): 118–31
 - **Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford.** *JNCI cancer spectrum*
Abrha, A., Shukla, N. D., Hodan, R., Longacre, T., Raghavan, S., Pritchard, C. C., Fisher, G., Ford, J., Haraldsdottir, S.
2020; 4 (5): pkaa054
 - **A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors**
Lopez, J. S., Camidge, R., Iafolla, M., Rottey, S., Schuler, M., Hellmann, M., Balmanoukian, A., Dirix, L., Gordon, M., Sullivan, R., Henick, B. S., Drake, C., Wong, et al
AMER ASSOC CANCER RESEARCH.2020
 - **Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study.** *The lancet. Gastroenterology & hepatology*
Lu, G., van den Berg, N. S., Martin, B. A., Nishio, N., Hart, Z. P., van Keulen, S., Fakurnejad, S., Chirita, S. U., Raymundo, R. C., Yi, G., Zhou, Q., Fisher, G. A., Rosenthal, et al
2020
 - **Extrahepatic Ga-68-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of Lu-177-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors**
Song, H., Kunz, P., Franc, B., Moradi, F., Fisher, G., Aparici, C., Iagaru, A., Davidzon, G.
SOC NUCLEAR MEDICINE INC.2020
 - **Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)**
Duan, H., Girod, B., Ninatti, G., Ferri, V., Kunz, P., Fisher, G., Moradi, F., Davidzon, G., Franc, B., Iagaru, A., Aparici, C.
SOC NUCLEAR MEDICINE INC.2020
 - **Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A two-year single institution experience**
Duan, H., Ninatti, G., Girod, B., Ferri, V., Guja, K., Song, H., Kunz, P., Fisher, G., Iagaru, A., Aparici, C.
SOC NUCLEAR MEDICINE INC.2020
 - **Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit.** *JCI insight*
Li, B., Jiang, Y., Li, G., Fisher, G. A., Li, R.
2020
 - **A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients**
Fisher, G. A., Lakhani, N. J., Eng, C., Hecht, J., Bendell, J. C., Philip, P., O'Dwyer, P. J., Johnson, B., Kardosh, A., Ippolito, T. M., Wang, Y. V., Agoram, B., Volkmer, et al
AMER SOC CLINICAL ONCOLOGY.2020
 - **Outcomes and Tolerability of Definitive and Preoperative Chemoradiation in Elderly Patients With Esophageal Cancer: A Retrospective Institutional Review.** *Advances in radiation oncology*
Rahimy, E. n., Koong, A. n., Toesca, D. n., White, M. N., Panjwani, N. n., Fisher, G. n., Chang, D. n., Pollom, E. n.

2020; 5 (6): 1188–96

- **Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.** *The oncologist*
Das, S. n., Ciombor, K. K., Haraldsdottir, S. n., Pumpalova, Y. n., Sahin, I. H., Pineda, G. n., Shyr, Y. n., Lin, E. P., Hsu, C. Y., Chu, S. K., Goff, L. W., Cardin, D. B., Bilien, et al
2020
- **Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-mesothelin (CRS-207) With or Without Nivolumab in Patients with Pancreatic Cancer.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
TsujiKawa, T. n., Crocenzi, T. n., Durham, J. N., Sugar, E. A., Wu, A. A., Onners, B. n., Nauroth, J. M., Anders, R. A., Fertig, E. J., Laheru, D. A., Reiss, K. n., Vonderheide, R. H., Ko, et al
2020
- **Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma.** *JCO precision oncology*
Whitman, J., Kardosh, A., Diaz, L., Fong, L., Hope, T., Onodera, C., Joseph, N., Le, D., Fisher, G., Bergsland, E.
2019; 3: 1-7
- **Feasibility and design of a cloud-based digital platform in patients with advanced cancer.**
Roy, M., Hall, E., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., San Pedro-Salcedo, M., Wakelee, H. A., Neal, J. W., Padda, S., Das, M., Fan, A. C., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer** *JOURNAL OF GASTROINTESTINAL ONCOLOGY*
Pumpalova, Y., Kozak, M. M., von Eyben, R., Kunz, P., Fisher, G., Chang, D. T., Haraldsdottir, S.
2019; 10 (4): 605–15
- **Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer.** *Journal of gastrointestinal oncology*
Pumpalova, Y., Kozak, M. M., von Eyben, R., Kunz, P., Fisher, G., Chang, D. T., Haraldsdottir, S.
2019; 10 (4): 605-615
- **Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.** *JAMA oncology*
O'Reilly, E. M., Oh, D., Dhani, N., Renouf, D. J., Lee, M. A., Sun, W., Fisher, G., Hezel, A., Chang, S., Vlahovic, G., Takahashi, O., Yang, Y., Fitts, et al
2019
- **Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer** *HPB*
Tummers, W. S., Miller, S. E., Teraphongphom, N. T., van den Berg, N. S., Hasan, A., Longacre, T. A., Fisher, G. A., Bonsing, B. A., Vahrmeijer, A. L., Gambhir, S. S., Swijnenburg, R., Rosenthal, E. L., Poultides, et al
2019; 21 (7): 883–90
- **A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients**
O'Hara, M. H., O'Reilly, E. M., Rosemarie, M., Varadhachary, G., Wainberg, Z. A., Ko, A., Fisher, G. A., Rahma, O., Lyman, J. P., Cabanski, C. R., Carpenter, E. L., Hollmann, T., Gherardini, et al
AMER ASSOC CANCER RESEARCH.2019
- **Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality.**
Leyden, S., Kolarova, T., Bouvier, C., Caplin, M. E., Conroy, S., Davies, P., Dureja, S., Falconi, M., Ferolla, P., Fisher, G. A., Goldstein, G., Hicks, R. J., Lawrence, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **ROCKET: A randomized, multicenter phase 2 study of RRx-001+irinotecan versus regorafenib in 3rd/4th line colorectal cancer.**
Reid, T. R., Fisher, G. A.
AMER SOC CLINICAL ONCOLOGY.2019
- **Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System**
Toesca, D. A. S., Jeffrey, R., von Eyben, R., Pollom, E. L., Poullos, P. D., Poultides, G. A., Fisher, G. A., Visser, B. C., Koong, A. C., Chang, D. T.

LIPPINCOTT WILLIAMS & WILKINS.2019: 622–28

- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers** *JOURNAL OF CLINICAL ONCOLOGY*
Sikic, B., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019; 37 (12): 946+
- **Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors** *ONCOLOGIST*
Pavel, M. E., Phan, A. T., Wolin, E. M., Mirakhur, B., Liyanage, N., Lowenthal, S., Fisher, G. A., Vinik, A. I., CLARINET Study Investigators
2019; 24 (4): 463–74
- **Lanreotide for the Prolonged Control of Carcinoid Syndrome (CS) in Somatostatin Analog (SSA)-Naive or -Experienced Patients**
Wolin, E., Fisher, G., Lowenthal, S., Mirakhur, B., Pommier, R., Shaheen, M., Vinik, A.
LIPPINCOTT WILLIAMS & WILKINS.2019: 455–56
- **Pancreatic Adenocarcinoma, Version 1.2019** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Tempero, M. A., Malafa, M. P., Chiorean, E., Czito, B., Scaife, C., Narang, A. K., Fountzilias, C., Wolpin, B. M., Al-Hawary, M., Asbun, H., Behrman, S. W., Benson, A. B., Binder, et al
2019; 17 (3): 203–10
- **Unmet Needs in the Global NETs Patient Community From the Perspectives of Patients, Patient Advocates, and NET Health Professionals**
Kolarova, T., Bouvier, C., Caplin, M., Conroy, S., Davies, P., Dureja, S., Falconi, M., Ferolla, P., Fisher, G., Goldstein, G., Hicks, R., Hollander, R., Lawrence, et al
LIPPINCOTT WILLIAMS & WILKINS.2019: 442
- **A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Trial of the ECOG-ACRIN Cancer Research Group (E2211)**
Kunz, P. L., Catalano, P., Nimeiri, H. S., Fisher, G. A., Longacre, T. A., Suarez, C. J., Yao, J. C., Kulke, M. H., Hendifar, A., Shanks, J. C., Shah, M. H., Zalupski, M. M., Schmulbach, et al
LIPPINCOTT WILLIAMS & WILKINS.2019: 443
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019: JCO1802018
- **Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer.** *HPB : the official journal of the International Hepato Pancreato Biliary Association*
Tummers, W. S., Miller, S. E., Teraphongphom, N. T., van den Berg, N. S., Hasan, A., Longacre, T. A., Fisher, G. A., Bonsing, B. A., Vahrmeijer, A. L., Gambhir, S. S., Swijnenburg, R., Rosenthal, E. L., Poultides, et al
2019
- **Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers.**
Shukla, N., Abrha, A., Longacre, T. A., Koff, R., Ford, J. M., Fisher, G. A., Haraldsdottir, S.
AMER SOC CLINICAL ONCOLOGY.2019
- **The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience.** *Cancer imaging : the official publication of the International Cancer Imaging Society*
Das, S., Pineda, G., Goff, L., Sobel, R., Berlin, J., Fisher, G.
2018; 18 (1): 47
- **Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.** *The oncologist*
Pavel, M. E., Phan, A. T., Wolin, E. M., Mirakhur, B., Liyanage, N., Pitman Lowenthal, S., Fisher, G. A., Vinik, A. I., CLARINET Study Investigators
2018
- **Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study.** *Pancreas*
Kardosh, A., Lichtensztajn, D. Y., Gubens, M. A., Kunz, P. L., Fisher, G. A., Clarke, C. A.
2018; 47 (8): 958–66

- **Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging.** *Annals of surgical oncology*
Tummers, W. S., Miller, S. E., Teraphongphom, N. T., Gomez, A., Steinberg, I., Huland, D. M., Hong, S., Kothapalli, S., Hasan, A., Ertsey, R., Bonsing, B. A., Vahrmeijer, A. L., Swijnenburg, et al
2018; 25 (7): 1880–88
- **Elevated Levels of 5-HIAA and CgA in Patients With Pancreatic Neuroendocrine Tumors (PanNETs): Analyses From the CLARINET Study**
Phan, A. T., Wolin, E. M., Liyanage, N., Mirakhur, B., Lowenthal, S., Vinik, A. I., Fisher, G. A., Pavel, M. E.
LIPPINCOTT WILLIAMS & WILKINS.2018: 350–51
- **5-Hydroxyindoleacetic Acid (5-HIAA) and Chromogranin A (CgA) as Biomarkers Secreted by Neuroendocrine Tumors (NETs): A Pooled Analysis of the ELECT and CLARINET Studies**
Fisher, G. A., Vinik, A. I., Pavel, M. E., Phan, A. T., Mirakhur, B., Massien, C., Liyanage, N., Pommier, R. F.
LIPPINCOTT WILLIAMS & WILKINS.2018: 339
- **Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study**
Pommier, R. F., Fisher, G. A., Wolin, E. M., Liyanage, N., Lowenthal, S., Mirakhur, B., Shaheen, M., Vinik, A. I.
LIPPINCOTT WILLIAMS & WILKINS.2018: 352
- **Change in Patient-Reported Symptom Control in Patients With Neuroendocrine Tumors Treated With Lanreotide Depot**
Wolin, E. M., Lowenthal, S., Fisher, G. A., Liyanage, N., Mirakhur, B., Pommier, R. F., Shaheen, M., Vinik, A. I.
LIPPINCOTT WILLIAMS & WILKINS.2018: 358
- **LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAIVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY** *ENDOCRINE PRACTICE*
Fisher, G. A., Wolin, E. M., Liyanage, N., Lowenthal, S., Mirakhur, B., Pommier, R. F., Shaheen, M., Vinik, A. I., ELECT Study Investigators
2018; 24 (3): 243–55
- **A first-in-class, first-in-human Phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.**
Sikic, B.
American Society of Clinical Oncology. 2018 ASCO Annual Meeting (June 1-5, 2018).
2018
- **Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor Patients.** *Journal of oncology and cancer research*
Das, S., Pineda, G., Berlin, J., Hemphill, B., Moslehi, J., Nohria, A., Fisher, G.
2018; 2: 23–27
- **Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study** *ONCOLOGIST*
Fisher, G. A., Wolin, E. M., Liyanage, N., Lowenthal, S., Mirakhur, B., Pommier, R. F., Shaheen, M., Vinik, A., ELECT Study Grp
2018; 23 (1): 16–24
- **A Phase 1b/2 Study of CD40 Agonistic Monoclonal Antibody (APX005M) Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Pancreatic Adenocarcinoma Patients.**
O'Hara, M., O'Reilly, E., Mick, R., Varadhachary, G., Wainberg, Z., Ko, A., Fisher, G., Lyman, J., Xu, J., LaVallee, T., Gherardini, P., Vance, B., Trifan, et al
American Society of Clinical Oncology. 2018 ASCO Annual Meeting (June 1-5, 2018).
2018
- **Change in Patient-Reported Symptom Control in Patients With Neuroendocrine Tumors Treated With Lanreotide Depot**
Wolin, E. M., Lowenthal, S., Fisher, G. A., Liyanage, N., Mirakhur, B., Pommier, R. F., Shaheen, M., Vinik, A. I.
NATURE PUBLISHING GROUP.2017: S652–S653
- **Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade** *SCIENCE*
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., Wong, F., Azad, N. S., Rucki, et al
2017; 357 (6349): 409–13

- **Reduced dose CT with model-based iterative reconstruction compared to standard dose CT of the chest, abdomen, and pelvis in oncology patients: intra-individual comparison study on image quality and lesion conspicuity.** *Abdominal radiology*
Morimoto, L. N., Kamaya, A., Boulay-Coletta, I., Fleischmann, D., Molvin, L., Tian, L., Fisher, G., Wang, J., Willmann, J. K.
2017
- **Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.** *Journal for immunotherapy of cancer*
Hege, K. M., Bergsland, E. K., Fisher, G. A., Nemunaitis, J. J., Warren, R. S., McArthur, J. G., Lin, A. A., Schlom, J., June, C. H., Sherwin, S. A.
2017; 5: 22-?
- **Quantitative Three-Dimensional Dynamic Contrast-Enhanced Ultrasound Imaging: First-In-Human Pilot Study in Patients with Liver Metastases** *THERANOSTICS*
El Kaffas, A., Sigrist, R., Fisher, G., Bachawal, S., Liau, J., Wang, H., Karanany, A., Durot, I., Rosenberg, J., Hristov, D., Willmann, J. K.
2017; 7 (15): 3745-58
- **Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer.** *Practical radiation oncology*
Rao, A. D., Sugar, E. A., Chang, D. T., Goodman, K. A., Hacker-Prietz, A., Rosati, L. M., Colombo, L., O'Reilly, E., Fisher, G. A., Zheng, L., Pai, J. S., Griffith, M. E., Laheru, et al
2016; 6 (6): 417-424
- **Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.** *Pancreas*
Kunz, P. L., Balise, R. R., Fehrenbacher, L., Pan, M., Venook, A. P., Fisher, G. A., Tempero, M. A., Ko, A. H., Korn, W. M., Hwang, J., Bergsland, E. K.
2016; 45 (10): 1394-1400
- **Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis.** *Surgery*
Cloyd, J. M., Kopecky, K. E., Norton, J. A., Kunz, P. L., Fisher, G. A., Visser, B. C., Dua, M. M., Park, W. G., Poultides, G. A.
2016; 160 (3): 708-713
- **EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.** *Endocrine practice*
Vinik, A. I., Wolin, E. M., Liyanage, N., Gomez-Panzani, E., Fisher, G. A.
2016; 22 (9): 1068-1080
- **CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer** *NEW ENGLAND JOURNAL OF MEDICINE*
Dalerba, P., Sahoo, D., Paik, S., Guo, X., Yothers, G., Song, N., Wilcox-Fogel, N., Forgo, E., Rajendran, P. S., Miranda, S. P., Hisamori, S., Hutchison, J., Kalisky, et al
2016; 374 (3): 211-222
- **CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.** *The New England journal of medicine*
Dalerba, P., Sahoo, D., Paik, S., Guo, X., Yothers, G., Song, N., Wilcox-Fogel, N., Forgo, E., Rajendran, P. S., Miranda, S. P., Hisamori, S., Hutchison, J., Kalisky, et al
2016; 374 (3): 211-22
- **The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.** *Redox biology*
Scicinski, J., Fisher, G., Carter, C., Cho-Phan, C., Kunz, P., Ning, S., Knox, S., Oronsky, B., Caroen, S., Parker, C., Fanger, G., Reid, T.
2015; 5: 422-?
- **PD-1 Blockade in Tumors with Mismatch-Repair Deficiency** *NEW ENGLAND JOURNAL OF MEDICINE*
Le, D. T., Uram, J. N., Wang, H., BARTLETT, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., Biedrzycki, B., Donehower, R. C., Zaheer, et al
2015; 372 (26): 2509-2520
- **A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).** *Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer*
Kunz, P. L., Catalano, P. J., Nimeiri, H. S., Fisher, G. A., Longacre, T. A., Schrijver, I., Reidy, D. L., Strosberg, J. R., O'Dwyer, P. J., Benson, A. B.
AMER SOC CLINICAL ONCOLOGY.2015

- **Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma** *CANCER*
Herman, J. M., Chang, D. T., Goodman, K. A., Dholakia, A. S., Raman, S. P., Hacker-Prietz, A., Iacobuzio-Donahue, C. A., Griffith, M. E., Pawlik, T. M., Pai, J. S., O'Reilly, E., Fisher, G. A., Wild, et al
2015; 121 (7): 1128-1137
- **Perspectives on clinical trials for gastrointestinal malignancies.** *American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting*
Eng, C., Roach, N., Longabaugh, M., Fisher, G.
2015: 40-43
- **Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method.** *Practical radiation oncology*
Goodman, K. A., Patton, C. E., Fisher, G. A., Hoffe, S. E., Haddock, M. G., Parikh, P. J., Kim, J. n., Baxter, N. N., Czito, B. G., Hong, T. S., Herman, J. M., Crane, C. H., Hoffman, et al
2015; 6 (3): 166-75
- **Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Pollom, E. L., Alagappan, M., von Eyben, R., Kunz, P. L., Fisher, G. A., Ford, J. A., Poultides, G. A., Visser, B. C., Norton, J. A., Kamaya, A., Cox, V. L., Columbo, L. A., Koong, et al
2014; 90 (4): 918-925
- **Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity.** *International journal of radiation oncology, biology, physics*
Pollom, E. L., Alagappan, M., von Eyben, R., Kunz, P. L., Fisher, G. A., Ford, J. A., Poultides, G. A., Visser, B. C., Norton, J. A., Kamaya, A., Cox, V. L., Columbo, L. A., Koong, et al
2014; 90 (4): 918-925
- **Limitations of Body Surface Area-Based Activity Calculation for Radioembolization of Hepatic Metastases in Colorectal Cancer** *JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY*
Lam, M. G., Louie, J. D., Abdelmaksoud, M. H., Fisher, G. A., Cho-Phan, C. D., Sze, D. Y.
2014; 25 (7): 1085-1093
- **Limitations of body surface area-based activity calculation for radioembolization of hepatic metastases in colorectal cancer.** *Journal of vascular and interventional radiology*
Lam, M. G., Louie, J. D., Abdelmaksoud, M. H., Fisher, G. A., Cho-Phan, C. D., Sze, D. Y.
2014; 25 (7): 1085-1093
- **Symptoms and palliative care needs of pancreatic adenocarcinoma patients.** *Journal of palliative medicine*
Luo, J., Chen, J. J., Deguzman, C., Mustian, K., Insko, M., Fisher, G., Palesh, O.
2014; 17 (6): 640-641
- **Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness.** *HPB*
Worhunsky, D. J., Krampitz, G. W., Poullos, P. D., Visser, B. C., Kunz, P. L., Fisher, G. A., Norton, J. A., Poultides, G. A.
2014; 16 (4): 304-311
- **Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors** *JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS*
Qadan, M., Ma, Y., Visser, B. C., Kunz, P. L., Fisher, G. A., Norton, J. A., Poultides, G. A.
2014; 218 (2): 188-195
- **Randomized Phase 2 Study of Pegylated SN-38 (EZN-2208) or Irinotecan Plus Cetuximab in Patients With Advanced Colorectal Cancer** *CANCER*
Garrett, C. R., Bekaii-Saab, T. S., Ryan, T., Fisher, G. A., Clive, S., Kavan, P., Shacham-Shmueli, E., Buchbinder, A., Goldberg, R. M.
2013; 119 (24): 4223-4230
- **Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?** *ANNALS OF SURGICAL ONCOLOGY*
Patel, M. I., Rhoads, K. F., Ma, Y., Ford, J. M., Visser, B. C., Kunz, P. L., Fisher, G. A., Chang, D. T., Koong, A., Norton, J. A., Poultides, G. A.
2013; 20 (5): 1631-1638

- **Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid Tumors Consensus Results From a Modified Delphi Process** *PANCREAS*
Strosberg, J. R., Fisher, G. A., Benson, A. B., Malin, J. L., Cherepanov, D., Broder, M. S.
2013; 42 (3): 397-404
- **Capecitabine-Induced Chest Pain Relieved by Diltiazem** *AMERICAN JOURNAL OF CARDIOLOGY*
Ambrosy, A. P., Kunz, P. L., Fisher, G. A., Witteles, R. M.
2012; 110 (11): 1623-1626
- **Long-Term Survivors of Gastric Cancer: A California Population-Based Study** *JOURNAL OF CLINICAL ONCOLOGY*
Kunz, P. L., Gubens, M., Fisher, G. A., Ford, J. M., Lichtensztajn, D. Y., Clarke, C. A.
2012; 30 (28): 3507-3515
- **Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features** *MODERN PATHOLOGY*
Chang, D. T., Pai, R. K., Rybicki, L. A., DiMaio, M. A., Limaye, M., Jayachandran, P., Koong, A. C., Kunz, P. A., Fisher, G. A., Ford, J. M., Welton, M., Shelton, A., Ma, et al
2012; 25 (8): 1128-1139
- **Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis** *ANNALS OF SURGICAL ONCOLOGY*
Poultides, G. A., Huang, L. C., Chen, Y., Visser, B. C., Pai, R. K., Jeffrey, R. B., Park, W. G., Chen, A. M., Kunz, P. L., Fisher, G. A., Norton, J. A.
2012; 19 (7): 2295-2303
- **A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer** *INVESTIGATIONAL NEW DRUGS*
Cabebe, E. C., Fisher, G. A., Sikic, B. I.
2012; 30 (3): 1082-1087
- **Medical treatment consensus in unresectable midgut gastrointestinal neuroendocrine tumors. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)**
Strosberg, J. R., Fisher, G. A., Benson, A. B., Malin, J. L., Anthony, L. B., Arslan, B., Gibbs, J. F., Greeno, E., Iyer, R. V., Kim, M. K., Maples, W., Philip, P. A., Wolin, et al
AMER SOC CLINICAL ONCOLOGY.2012
- **A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Padda, S. K., Krupitskaya, Y., Chhatwani, L., Fisher, G. A., Colevas, A. D., Pedro-Salcedo, M. S., Decker, R., Latz, J. E., Wakelee, H. A.
2012; 69 (4): 1013-1020
- **Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma 51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)**
Abelson, J. A., Murphy, J. D., Minn, A. Y., Chung, M., Fisher, G. A., Ford, J. M., Kunz, P., Norton, J. A., Visser, B. C., Poultides, G. A., Koong, A. C., Chang, D. T.
ELSEVIER SCIENCE INC.2012: E595-E601
- **HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment** *APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY*
Kunz, P. L., Mojtahed, A., Fisher, G. A., Ford, J. M., Chang, D. T., Balise, R. R., Bangs, C. D., Cherry, A. M., Pai, R. K.
2012; 20 (1): 13-24
- **Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies** *INVESTIGATIONAL NEW DRUGS*
Galatin, P. S., Advani, R. H., Fisher, G. A., Francisco, B., Julian, T., Losa, R., Sierra, M. I., Sikic, B. I.
2011; 29 (5): 971-977
- **Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal** *CANCER*
Bazan, J. G., Hara, W., Hsu, A., Kunz, P. A., Ford, J., Fisher, G. A., Welton, M. L., Shelton, A., Kapp, D. S., Koong, A. C., Goodman, K. A., Chang, D. T.
2011; 117 (15): 3342-3351
- **Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for Resection** *ARCHIVES OF SURGERY*

- Norton, J. A., Harris, E. J., Chen, Y., Visser, B. C., Poultides, G. A., Kunz, P. C., Fisher, G. A., Jensen, R. T.
2011; 146 (6): 724-732
- **F-18-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases** *NUCLEAR MEDICINE COMMUNICATIONS*
Zissen, M. H., Kunz, P., Subbarayan, M., Chin, F. T., Conti, P. S., Fisher, G. A., Quon, A.
2011; 32 (5): 343-347
 - **Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting** *JOURNAL OF CLINICAL ONCOLOGY*
Kulke, M. H., Siu, L. L., Tepper, J. E., Fisher, G., Jaffe, D., Haller, D. G., Ellis, L. M., Benedetti, J. K., Bergsland, E. K., Hobday, T. J., Van Cutsem, E., Pingpank, J., Oberg, et al
2011; 29 (7): 934-943
 - **Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma** *51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)*
Chang, D. T., Chapman, C. H., Norton, J. A., Visser, B., Fisher, G. A., Kunz, P., Ford, J. M., Koong, A. C., Pai, R. K.
WILEY-BLACKWELL.2010: 5179-87
 - **Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer** *51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)*
Minn, A. Y., Hsu, A., La, T., Kunz, P., Fisher, G. A., Ford, J. M., Norton, J. A., Visser, B., Goodman, K. A., Koong, A. C., Chang, D. T.
JOHN WILEY & SONS INC.2010: 3943-52
 - **(18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Schellenberg, D., Quon, A., Minn, A. Y., Graves, E. E., Kunz, P., Ford, J. M., Fisher, G. A., Goodman, K. A., Koong, A. C., Chang, D. T.
2010; 77 (5): 1420-1425
 - **Pathological response after chemoradiation for T3 rectal cancer.** *Colorectal disease*
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., Itakura, H., Welton, M. L., Shelton, A., Van Dam, J., Koong, A. C., Chang, D. T.
2010; 12 (7 Online): e24-30
 - **Pathological response after chemoradiation for T3 rectal cancer** *COLORECTAL DISEASE*
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., Itakura, H., Welton, M. L., Shelton, A., Van Dam, J., Koong, A. C., Chang, D. T.
2010; 12 (7): E24-E30
 - **Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors** *ANNALS OF ONCOLOGY*
Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M., Fox, N. L., Miceli, R., Ullrich, S. J., Fisher, G. A., Tolcher, A. W.
2010; 21 (2): 376-381
 - **Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.** *Clinical and experimental gastroenterology*
Kunz, P. L., Fisher, G. A.
2010; 3: 79-86
 - **Multimodality treatment with intensity modulated radiation therapy for esophageal cancer** *DISEASES OF THE ESOPHAGUS*
La, T. H., Minn, A. Y., Su, Z., Fisher, G. A., Ford, J. M., Kunz, P., Goodman, K. A., Koong, A. C., Chang, D. T.
2010; 23 (4): 300-308
 - **Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis** *JOURNAL OF TRANSLATIONAL MEDICINE*
Chang, S. T., Zahn, J. M., Horecka, J., Kunz, P. L., Ford, J. M., Fisher, G. A., Le, Q. T., Chang, D. T., Ji, H., Koong, A. C.
2009; 7
 - **Impaired interferon signaling is a common immune defect in human cancer** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Critchley-Thorne, R. J., Simons, D. L., Yan, N., Miyahira, A. K., Dirbas, F. M., Johnson, D. L., Swetter, S. M., Carlson, R. W., Fisher, G. A., Koong, A., Holmes, S., Lee, P. P.
2009; 106 (22): 9010-9015

- **Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas** *CANCER*
Chang, D. T., Schellenberg, D., Shen, J., Kim, J., Goodman, K. A., Fisher, G. A., Ford, J. M., Desser, T., Quon, A., Koong, A. C.
2009; 115 (3): 665-672
- **Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Schellenberg, D., Goodman, K. A., Lee, F., Chang, S., Kuo, T., Ford, J. M., Fisher, G. A., Quon, A., Desser, T. S., Norton, J., Greco, R., Yang, G. P., Koong, et al
2008; 72 (3): 678-686
- **A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer** *CLINICAL CANCER RESEARCH*
Fischer, G., Kuo, T., Ramsey, M., Schwartz, E., Rouse, R., Cho, C. D., Halsey, J., Sikic, B. I.
2008; 14 (21): 7074-7079
- **Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate** *ANNALS OF ONCOLOGY*
Telli, M. L., Witteles, R. M., Fisher, G. A., Srinivas, S.
2008; 19 (9): 1613-1618
- **Tissue effects after stereotactic body radiotherapy using cyberknife for patients with abdominal malignancies** *CLINICAL ONCOLOGY*
Cupp, J. S., Koong, A. C., Fisher, G. A., NORTON, J. A., Goodman, K. A.
2008; 20 (1): 69-75
- **Phase H study of imatinib in unresectable hepatocellular carcinoma** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Lin, A. Y., Fisher, G. A., So, S., Tang, C., Levitt, L.
2008; 31 (1): 84-88
- **NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.** *Journal of the National Comprehensive Cancer Network*
Demetri, G. D., Benjamin, R. S., Blanke, C. D., Blay, J., Casali, P., Choi, H., Corless, C. L., Debiec-Rychter, M., DeMatteo, R. P., Ettinger, D. S., Fisher, G. A., Fletcher, C. D., Gronchi, et al
2007; 5: S1-29
- **Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer** *EXPERT OPINION ON INVESTIGATIONAL DRUGS*
Cabebe, E., Fisher, G. A.
2007; 16 (4): 467-476
- **Phase I study of I-131-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer** *CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS*
Street, H. H., Goris, M. L., Fisher, G. A., Wessels, B. W., Cho, C., Hernandez, C., Zhu, H. J., Zhang, Y., Nangiana, J. S., Shan, J. S., Roberts, K., Knox, S. J.
2006; 21 (3): 243-256
- **Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies** *INVESTIGATIONAL NEW DRUGS*
Cho, C. D., Fisher, G. A., Halsey, J., Sikic, B. I.
2006; 24 (2): 117-123
- **A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance** *ANNALS OF ONCOLOGY*
Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., Jacobs, C. D., Sikic, B. I.
2005; 16 (12): 1968-1973
- **Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.** *Clinical colorectal cancer*
Kuo, T., Fisher, G. A.
2005; 5: S62-70
- **A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer** *36th Annual Meeting of the American-Society-of-Clinical-Oncology*
Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Geary, R. S., Holmlund, J. T., Kwoh, T. J., DORR, F. A., Sikic, B. I.

SPRINGER.2005: 467–77

- **Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Koong, A. C., Christofferson, E., Le, Q. T., Goodman, K. A., Ho, A., Kuo, T., Ford, J. M., Fisher, G. A., Greco, R., Norton, J., Yang, G. P.
2005; 63 (2): 320-323
- **Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer** *40th Annual Meeting of the American-Society-of-Clinical-Oncology*
Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., Ford, J. M., Fisher, G. A., Sikic, B. I.
AMER SOC CLINICAL ONCOLOGY.2005: 5613–19
- **A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer** *INVESTIGATIONAL NEW DRUGS*
Wakelee, H., Fisher, G. A.
2005; 23 (3): 241-242
- **Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma** *CANCER*
Lin, A. Y., Brophy, N., Fisher, G. A., So, S., Biggs, C., Yock, T. I., Levitt, L.
2005; 103 (1): 119-125
- **Phase I study of I-131-chimeric(ch) TNT-1/B antibody for the treatment of advanced colorectal cancer** *10th Conference on Cancer Therapy with Antibodies and Immunoconjugates*
Knox, S., Fisher, G., Wessels, B., Cho, C., Hernandez, M. C., Street, H., Nangiana, J., Shan, J., Goris, M.
MARY ANN LIEBERT INC.2004: 528–28
- **Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Koong, A. C., Le, Q. T., Ho, A., Fong, B., Fisher, G., Cho, C., Ford, J., Poen, J., Gibbs, I. C., Mehta, V. K., Kee, S., Trueblood, W., Yang, et al
2004; 58 (4): 1017-1021
- **A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma** *36th Annual Meeting of the American-Society-of-Clinical-Oncology*
Advani, R., Peethambaram, P., Lum, B. L., Fisher, G. A., Hartmann, L., Long, H. J., Halsey, J., Holmlund, J. T., Dorr, A., Sikic, B. I.
JOHN WILEY & SONS INC.2004: 321–26
- **The Stanford experience with preoperative chemoradiation using CPT-11 and 5-FU in locally advanced rectal cancer: Toxicities and outcomes** *46th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology*
Tillman, G. F., Fisher, G., Cho, C., Ford, J. M., Mehta, V. K., Welton, M., Shelton, A., Bastidas, J. A., Young, H., Koong, A.
ELSEVIER SCIENCE INC.2004: S417–S418
- **A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer.** *AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics*
Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., Rouse, R. V., Advani, R. H., Wakelee, H. A., Lum, B. L., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2003: 6103S–6103S
- **Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies** *CLINICAL CANCER RESEARCH*
Advani, R., Fisher, G. A., Lum, B. L., Jambalos, C., Cho, C. D., Cohen, M., Gollerkeri, A., Sikic, B. I.
2003; 9 (14): 5187-5194
- **Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Mehta, V. K., Cho, C., Ford, J. M., Jambalos, C., Poen, J., Koong, A., Lin, A., Bastidas, J. A., Young, H., Dunphy, E. P., Fisher, G.
2003; 55 (1): 132-137
- **A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies** *14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics*
Fisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., Lum, B. L., Sikic, B. I.
ELSEVIER SCI LTD.2002: S63–S63
- **The effect of oral valsopodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin.**
Lum, B. L., Chin, D. L., Cho, C. D., Advani, R., Fisher, G. A., Halsey, J., Sikic, B. I.

NATURE PUBLISHING GROUP.2002: P48–P48

- **Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound staged T3 rectal cancer**
Mehta, V. K., Poen, J. C., Ford, J., Young, H., Cho, C., Fisher, G.
LIPPINCOTT WILLIAMS & WILKINS.2001: 539–39
- **Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Fong, L., Hou, Y. F., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., DAVIS, M. M., Engleman, E. G.
2001; 98 (15): 8809-8814
- **A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance** *34th Annual Meeting of the American-Society-of-Clinical-Oncology*
Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litchman, M., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2001: 1221–29
- **Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Mehta, V. K., Poen, J. C., Ford, J. M., Oberhelman, H. A., Vierra, M. A., Bastidas, A. J., Fisher, G. A.
2001; 24 (2): 155-159
- **Center experience in liver transplantation for hepatocellular carcinoma associated with cirrhosis** *18th World Congress of the Transplantation-Society*
Lai, K. M., MILLAN, M., Razavi, M., Keeffe, E. B., Prapong, W., Fisher, G. A., Esquivel, C. O., So, S. K.
ELSEVIER SCIENCE INC.2001: 1490–91
- **Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas** *82nd Annual Meeting of the American-Radium-Society*
Mehta, V. K., Fisher, G., Ford, J. A., Poen, J. C., Vierra, M. A., Oberbelman, H., Niederhuber, J., Bastidas, J. A.
SPRINGER.2001: 27–35
- **Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer** *36th Annual Meeting of the American-Society-of-Clinical-Oncology*
Mehta, V. K., Poen, J., Ford, J., Edelstein, P. S., Vierra, M., Bastidas, A. J., Young, H., Fisher, G.
SPRINGER.2001: 52–58
- **Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report** *ARCHIVES OF SURGERY*
Mehta, V. K., Fisher, G. A., Ford, J. M., Poen, J. C., Vierra, M. A., Oberhelman, H. A., Bastidas, A. J.
2001; 136 (1): 65-69
- **Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Mehta, V. K., Fisher, G. A., Ford, J. M., Oberhelman, H. A., Vierra, M. A., Bastidas, A. J., Poen, J. C.
2000; 48 (5): 1483-1487
- **Pancreatic tumors show high levels of hypoxia** *36th Annual Meeting of the American-Society-of-Clinical-Oncology*
Koong, A. C., Mehta, V. K., Le, Q. T., Fisher, G. A., Terris, D. J., Brown, J. M., Bastidas, A. J., Vierra, M.
ELSEVIER SCIENCE INC.2000: 919–22
- **Liver transplantation for hepatocellular carcinoma and the role of preoperative chemoembolization.**
Millan, M. T., Lai, K. M., Keeffe, E. B., Fisher, G. A., Razavi, M. K., Prapong, W., Barry, C. T., Esquivel, C. O., So, S. K.
LIPPINCOTT WILLIAMS & WILKINS.2000: S215–S215
- **Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Lum, B. L., Kaubisch, S., Fisher, G. A., Brown, B. W., Sikic, B. I.
2000; 45 (4): 305-311
- **Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer** *CLINICAL CANCER RESEARCH*
Yuen, A. R., Halsey, J., Fisher, G. A., Holmlund, J. T., Geary, R. S., Kwoh, T. J., Dorr, A., Sikic, B. I.

1999; 5 (11): 3357-3363

- **Chemo-radiotherapy for localized pancreatic cancer: Increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil** *Conference on Overcoming Bad Blood in Cancer Clinical Trials - Tuskegee Trial Revisited*
Poeh, J. C., Collins, H. L., Niederhuber, J. E., Oberhelman, H. A., Vierra, M. A., Bastidas, A. J., Young, H. S., Slosberg, E. A., Jeffrey, B. R., Longacre, T. A., Fisher, G. A., Goffinet, D. R.
ELSEVIER SCIENCE INC.1998: 93–99
- **Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein** *12th Bristol-Myers-Squibb Nagoya International Cancer Treatment Symposium*
Sikic, B. I., Fisher, G. A., Lum, B. L., Halsey, J., BEKETICORESKOVIC, L., Chen, G.
SPRINGER.1997: S13–S19
- **Clinical decision making based on radionuclide determined ejection fraction in oncology patients** *JOURNAL OF NUCLEAR MEDICINE*
Peng, N. J., Advani, R., Kapiwoda, S., Fisher, G., Strauss, H. W.
1997; 38 (5): 702-705
- **Pharmacological considerations in the modulation of multidrug resistance** *EUROPEAN JOURNAL OF CANCER*
Fisher, G. A., Lum, B. L., Hausdorff, J., Sikic, B. I.
1996; 32A (6): 1082-1088
- **Drug resistance in clinical oncology and hematology. Introduction.** *Hematology/oncology clinics of North America*
Fisher, G. A., Sikic, B. I.
1995; 9 (2): xi-xii
- **CLINICAL-STUDIES WITH MODULATORS OF MULTIDRUG-RESISTANCE** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Fisher, G. A., Sikic, B. I.
1995; 9 (2): 363-382
- **The reversal of multidrug resistance.** *Cancer treatment and research*
Fisher, G. A., Lum, B. L., Sikic, B. I.
1995; 78: 45-70
- **MAMMALIAN-CELL SURVIVAL STUDIES CHARACTERIZING MULTIPOINT NEGATIVE PI-MESON IRRADIATION WITH THE STANFORD MEDICAL PION GENERATOR (SMPG)** *INTERNATIONAL JOURNAL OF HYPERTHERMIA*
Li, G. C., Fessenden, P., Hahn, G. M., Fisher, G., Luxton, G., Bagshaw, M. A.
1994; 10 (3): 361-370
- **PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE** *JOURNAL OF CLINICAL ONCOLOGY*
Bartlett, N. L., Lum, B. L., Fisher, G. A., BROPHY, N. A., EHSAN, M. N., Halsey, J., Sikic, B. I.
1994; 12 (4): 835-842
- **Clinical reversal of multidrug resistance.** *Cancer treatment and research*
Sikic, B. I., Fisher, G. A., Lum, B. L., BROPHY, N. A., Yahanda, A. M., ADLER, K. M., Halsey, J.
1994; 73: 149-165
- **CLINICAL-TRIALS OF MODULATION OF MULTIDRUG-RESISTANCE - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS** *2nd national conference on new oncologic agents : Practical applications*
Lum, B. L., Fisher, G. A., BROPHY, N. A., Yahanda, A. M., ADLER, K. M., Kaubisch, S., Halsey, J., Sikic, B. I.
WILEY-LISS.1993: 3502–14
- **REVERSAL OF MULTIDRUG-RESISTANCE TO CANCER-CHEMOTHERAPY** *2nd national conference on new oncologic agents : Practical applications*
LEYLANDJONES, B., Dalton, W., Fisher, G. A., Sikic, B. I.
WILEY-LISS.1993: 3484–88
- **THE MODULATION OF MULTIDRUG-RESISTANCE - CLINICAL-STUDIES AT STANFORD** *INTERNATIONAL SYMP ON THE MECHANISM AND NEW APPROACH ON DRUG RESISTANCE OF CANCER CELLS*
Fisher, G. A., BROPHY, N. A., Yahanda, A. M., Adler, K. A., Lum, B. L., Bartlett, N. L., Halsey, J., Sikic, B. I.
ELSEVIER SCIENCE PUBL B V.1993: 255–266

- **PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE** *JOURNAL OF CLINICAL ONCOLOGY*
Yahanda, A. M., ADLER, K. M., Fisher, G. A., BROPHY, N. A., Halsey, J., Hardy, R. I., Gosland, M. P., Lum, B. L., Sikic, B. I.
1992; 10 (10): 1624-1634
- **DNA DAMAGE DOES NOT APPEAR TO BE A TRIGGER FOR THERMOTOLERANCE IN MAMMALIAN-CELLS** *INTERNATIONAL JOURNAL OF RADIATION BIOLOGY*
Anderson, R. L., Shiu, E., Fisher, G. A., Hahn, G. M.
1988; 54 (2): 285-298
- **CORRELATION OF MAMMALIAN-CELL KILLING BY HEAT-SHOCK TO INTRAMEMBRANOUS PARTICLE AGGREGATION AND LATERAL PHASE-SEPARATION USING FLUORESCENCE-ACTIVATED CELL SORTING** *RADIATION RESEARCH*
RICE, G. C., Fisher, K. A., Fisher, G. A., Hahn, G. M.
1987; 112 (2): 351-364
- **INDUCTION OF THERMOTOLERANCE AND EVIDENCE FOR A WELL-DEFINED, THERMOTROPIC COOPERATIVE PROCESS** *RADIATION RESEARCH*
Li, G. C., Fisher, G. A., Hahn, G. M.
1982; 89 (2): 361-368
- **MODIFICATION OF THE THERMAL RESPONSE BY D2O .2. THERMOTOLERANCE AND THE SPECIFIC-INHIBITION OF DEVELOPMENT** *RADIATION RESEARCH*
Li, G. C., Fisher, G. A., Hahn, G. M.
1982; 92 (3): 541-551
- **MODIFICATION OF THE THERMAL RESPONSE BY D2O .1. CELL-SURVIVAL AND THE TEMPERATURE SHIFT** *RADIATION RESEARCH*
Fisher, G. A., Li, G. C., Hahn, G. M.
1982; 92 (3): 530-540
- **Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System.** *Pancreas*
Toesca, D. A., Jeffrey, R. B., von Eyben, R. n., Pollom, E. L., Poullos, P. D., Poultsides, G. A., Fisher, G. A., Visser, B. C., Koong, A. C., Chang, D. T.
; 48 (5): 622-28